BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing - 2Remote Headphones: Upgrade Your Sound Insight
- 3Authorities Bust Camel Booze Smuggling Operation, Seize Nearly 2,000 Containers of Illegal Alcohol
- 4Famous SUVs With Low Energy Utilization In 2024
- 5Ukraine proved this drone-killer works. Now, the West is giving it a shot.
- Alleged Huione Group Money Laundering Boss Extradited to China
- Figuring out the Justification for Separation: To blame and No-Shortcoming
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Indian Health Service is digging out of decades-old construction backlog for medical buildings
- Pick Your Favored kind of sandwich
- Shadow Cats: The Elusive Leopards Surviving Against Impossible Odds
- Germany's far-right AfD tops poll ahead of Merz's conservatives
- We may have less control over how long we live than previously thought
- Investigating the World's Chief Authentic Urban communities to Visit
